PharmaFluidics Raises 7.3 Million Euro to Expand Commercialization of Novel Microchip Device for Biomarker, Diagnostics and Drug Development Applications

PharmaFluidics NV announced in January that it has raised 7.3 million euro. The company will focus on intensifying international growth, supported by initial, promising sales. The financing came from investors including holding company FPIM-SFPI, and family offices Heran (Annie Vereecken) and RMM (Rudi Mariën). The existing investors PMV, Qbic, Theodorus, Innovation Fund and Volksvermogen reaffirm their confidence in the company and also participated in this financing round.

The VUB spin-off has a unique technology, the µPACᵀᴹ column series, which offers robust and reproducibile, sensitive peformance, at high-resolution. The first clients – academic labs in bioanalysis, biopharmaceuticals and diagnostics companies – have confirmed these outstanding characteristics of the µPACᵀᴹ technology.

The new funds will be used to further develop the Pillar Array technology platform, to expand the µPACᵀᴹ product range, and to scale up production and global sales.

Intensified Commercialization
The company started shipping µPACᵀᴹ columns in September 2017 and has since served proteomics laboratories, medical centers and pharmaceutical companies on three continents: Europe, the USA and Asia. Its pioneering product is very well received and has convinced pioneer users and key opinion leaders in proteomics to use microchip based chromatography.

The performance of the µPACᵀᴹ columns brings groundbreaking applications within reach. For example, the robustness and reproducibility allow proteomics data from different labs to be pooled, making reliable big data analysis possible. The miniaturization and sensitivity open the door to point-of-care nano-LC-MS, or ultimately single-cell analyses. This market validation as well as the additional potential in new markets have convinced serial life sciences investors RMM SA and Heran BVBA to participate in the current funding round.

Leave a Reply